Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

January 2022; 9 (1) EditorialOpen Access

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade

Kok Pin Yong, View ORCID ProfileHo Jin Kim
First published December 15, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001110
Kok Pin Yong
From the Department of Neurology (K.P.Y.), National Neuroscience Institute (Singapore General Hospital); Duke-NUS Medical School (K.P.Y.), Singapore; and Department of Neurology (H.J.K.), Research Institute and Hospital of National Cancer Center, Goyang, Korea.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yong.kok.pin@singhealth.com.sg
Ho Jin Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ho Jin Kim
Full PDF
Citation
Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
Kok Pin Yong, Ho Jin Kim
Neurol Neuroimmunol Neuroinflamm Jan 2022, 9 (1) e1110; DOI: 10.1212/NXI.0000000000001110

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
733

Share

  • Article
  • Info & Disclosures
Loading

Myelin oligodendrocyte glycoprotein-IgG (MOG-IgG)-associated disorder (MOGAD) is a recently defined neuroimmunologic disorder affecting the CNS, commonly presenting with acute disseminated encephalomyelitis in children and with optic neuritis and/or myelitis in adults. Although some patients, especially children, may exhibit a monophasic course, there are others who tend to run a highly relapsing course, potentially resulting in long-lasting neurologic disability, akin to those with neuromyelitis optica spectrum disorder (NMOSD).1 In fact, up to almost half of patients with NMOSD without aquaporin-4 (AQP4-IgG) harbor MOG-IgG.2 In addition, despite comprehensive testing for aquaporin-4 antibodies, there remains a proportion of patients who phenotypically resemble those with NMOSD but are seronegative for both AQP4-IgG and MOG-IgG.3

Recent key phase II and III international, randomized, double-blind, placebo-controlled trials in patients with NMOSD, especially with AQP4-IgG, used drugs with specific immunopathogenic targets and were met with good outcomes in reducing the risk of relapse.4,-,7 Among these was satralizumab, a humanized monoclonal antibody targeting interleukin-6 receptor (IL-6R). The efficacy of satralizumab, as a monotherapy or as add-on therapy, demonstrated the essential role of interleukin-6 (IL-6) in the pathophysiology of NMOSD with contributions toward inflammatory Th17 cell development, production of AQP4-IgG via plasmablasts stimulation, and increased CNS permeability through blood-brain barrier dysfunction.8 Tocilizumab, another humanized IL-6 receptor inhibitor, emerged as a promising therapeutic option after few case series and a prospective, multicenter, randomized, open label phase II study provided further evidence for NMOSD relapse risk reduction.9,-,12 Similar to satralizumab, most participants in this tocilizumab trial had AQP4-IgG. On the contrary, double-seronegative patients with NMOSD did not seem to respond as well to satralizumab and inebilizumab, with none of these patients included in the eculizumab trial. As for patients with MOGAD, they were either under or unrepresented in these successful studies.

Furthermore, the evidence for efficacy of rituximab, a CD20-mediated B cell-depleting monoclonal antibody, has been less compelling for MOGAD when juxtaposed with AQP4-IgG+ NMOSD.13,14 In the prospective observational study by Durozard et al., patients with MOGAD relapsed more frequently (37.5% vs 24%) and earlier (2.6 vs 7 months; median time after last rituximab infusion) as compared to those with AQP4-IgG+ NMOSD. Of note, there were more patients in the MOGAD group who relapsed despite effective B cell depletion while re-emergence of memory B cells was observed in all except 1 of the patients with AQP4-IgG+ NMOSD who relapsed.13 The lesser effect of rituximab on MOGAD as contrasted with AQP4-IgG+ NMOSD was echoed in another large retrospective multicenter study involving 121 patients. Likewise, a high number of relapses in MOGAD occurred with apparent adequate B cell depletion.14 The optimal treatment strategy remains unclear in MOGAD, particularly for those with a relapsing course, and in double-seronegative NMOSD.

Consequently, the findings of Ringelstein et al.15 published in this issue of Neurology®: Neuroimmunology and Neuroinflammation are timely and important. In this retrospective, multicenter study, a total of 57 patients with MOGAD, AQP4-IgG+ NMOSD, and seronegative NMOSD had a reduction in median annualized relapse rate (ARR) after receiving tocilizumab for at least 12 months and median treatment duration of 23.8 months. The absence of additional benefit conferred by background therapy further lends support to tocilizumab as a promising monotherapy. All had received various immunotherapies, especially rituximab before treatment initiation with tocilizumab. Equally appealing was the assuring safety profile, which was observed over a span of maximum treatment duration of nearly 9 years.

Retrospective studies are fraught with potential sources of bias inherent to its design. The authors have highlighted some of these including the lack of data homogeneity (e.g., differing treatment and MRI protocols) and availability. The relatively small number of study participants (14 patients with MOGAD, 7 with double-seronegative NMOSD, and 36 with AQP4-IgG+ NMOSD) may also diminish the overall study effect. However, these limitations are not entirely surprising, given the rarity of MOGAD and NMOSD, with or without AQP4-IgG. These limitations should not undo the collective effort and good work by the authors from an international network.

Immunopathogenic mechanisms that are different from those underpinning AQP4-IgG+ NMOSD may, at least in part, contribute to the observed discrepant therapeutic response by MOGAD and double-seronegative patients with NMOSD. Further effort in elucidating the distinct disease mechanisms will shape the appropriate therapeutic recommendations with the main goal to prevent relapse recurrence and hence cumulative neurologic disabilities. Indeed, there have been recent studies demonstrating pathologic features in MOGAD that are different from those occurring in AQP4-IgG+ NMOSD.16,17 In the same line of investigations and in our experience, significantly lower levels of CSF glial fibrillary acidic protein levels were detected in double-seronegative patients with NMOSD compared with those with AQP4-IgG during clinical relapses, suggesting a distinct pathophysiology to the established astrocytopathic process of AQP4-IgG+ NMOSD (unpublished).

Positive outcomes as a result of tocilizumab usage, both in efficacy and effectiveness as well as its safety profile, offer a potentially additional treatment option to physicians and patients, either as monotherapy or a switch over from preceding immunotherapy especially in refractory cases. Although the current observation is encouraging, larger confirmatory studies (ideally randomized and controlled) including MOGAD and double-seronegative patients with NMOSD with long-term follow-up are warranted. Nonetheless, Ringelstein et al. have provided us with a platform to build further with this real-world study, involving the largest number of patients with MOGAD to date. Although, in recent years, we have witnessed an expansion of the therapeutic landscape for AQP4-IgG+ NMOSD patients, these findings continue to lend a hand in demystifying MOGAD and double-seronegative NMOSD.

Study Funding

No targeted funding reported.

Disclosure

K.P. Yong has received honorarium from Merck. H.J. Kim has received a grant from the National Research Foundation of Korea and research support from Aprilbio and Eisai; received consultancy/speaker fees from Alexion, Aprilbio, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, MDimune, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, UCB, and Viela Bio; is a coeditor for the MS Journal and an associated editor for the Journal of Clinical Neurology. Go to Neurology.org/NN for full disclosures.

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • See page e1100

  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Reindl M,
    2. Waters P
    . Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89-102.
    OpenUrlPubMed
  2. 2.↵
    1. Hamid SHM,
    2. Whittam D,
    3. Mutch K, et al.
    What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088-2094.
    OpenUrl
  3. 3.↵
    1. Sepúlveda M,
    2. Armangué T,
    3. Sola-Valls N, et al
    . Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e225.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Pittock SJ,
    2. Berthele A,
    3. Fujihara K, et al
    . Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-625.
    OpenUrlPubMed
  5. 5.↵
    1. Cree BAC,
    2. Bennett JL,
    3. Kim HJ, et al.
    Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomized placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Yamamura T,
    2. Kleiter I,
    3. Fujihara K, et al
    . Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-2124.
    OpenUrlPubMed
  7. 7.↵
    1. Traboulsee A,
    2. Greenberg BM,
    3. Bennett JL, et al.
    Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicenter, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412.
    OpenUrl
  8. 8.↵
    1. Fujihara K,
    2. Bennett JL,
    3. de Seze J, et al
    . Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ayzenberg I,
    2. Kleiter I,
    3. Schröder A, et al
    . Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394-397.
    OpenUrl
  10. 10.↵
    1. Araki M,
    2. Matsuoka T,
    3. Miyamoto K, et al
    . Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82(15):1302-1306.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ringelstein M,
    2. Ayzenberg I,
    3. Harmel J, et al
    . Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756-763.
    OpenUrl
  12. 12.↵
    1. Zhang C,
    2. Zhang M,
    3. Qiu W, et al
    . Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401.
    OpenUrlCrossRef
  13. 13.↵
    1. Durozard P,
    2. Rico A,
    3. Boutiere C, et al
    . Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020;87(2):256-266.
    OpenUrlPubMed
  14. 14.↵
    1. Whittam DH,
    2. Cobo-Calvo A,
    3. Lopez-Chiriboga AS, et al
    . Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.
    OpenUrlPubMed
  15. 15.↵
    1. Ringelstein M,
    2. Ayzenberg I,
    3. Lindeblatt G, et al.
    Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1100.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Höftberger R,
    2. Guo Y,
    3. Flanagan EP, et al
    . The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875-892.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Takai Y,
    2. Misu T,
    3. Kaneko K, et al
    . Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. 2020;143(5):1431-1446.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study Funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

Topics Discussed

  • All Demyelinating disease (CNS)
  • Autoimmune diseases

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise